References
- Miramanoff M. Unpublished data presented at Perspectives in CNS Malignancies IV in Berlin March 28-29, 2008
- Stark-Vance V. Bevacizumab and CPT-11 in the treatment of relapsed malignant glioma. J Neurooncol 2005;7:369( Abstract 342).
- Vredenburgh JJ, Desjardins A, Herndon JE, Marcello J, Reardon DA, et al. Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. J Clin Oncol 2007; 25: 4722–9
- Skovgaard-Poulsen H, Grunnet K, Sorensen M, Hasselbach B, Nelausen K, Kosteljanetz M, et al Adult primary brain tumour patients with a history of multiple recurrences: Results of treatment with an angiogenesis inhibitor, bevacizumab, combined with irinotecan. Acta Oncol ( in press).
- Louis DN, Oghaki H, Wiestler OD, Cavenee WK. WHO classification of tumours in the central nervous system. 2007; IARC.
- Hicklin DJ, Ellis LM. Role of the VEGFR pathway in tumour growth and angiogenesis. J Clin Oncol 2005; 23: 1011–27
- Johansson M, Brännström T, Bergenheim AT, Henriksson R. Spatial expression of VEGF-A in human glioma. J Neurooncol 2002; 59: 1–6
- Sandström M, Johansson M, Bergström P, Bergenheim AT, Henriksson R. Effects of the VEGFR inhibitor ZD6474 in combination with radiotherapy and temozolomide in an orthotopic glioma model. J Neurooncol 2008; 88: 1–9
- Jain RK, di Tomaso E, Duda DG, Loeffler JS, Sorensen AG, Batchelor TT. Angiogenesis in brain tumours. Nat Rev Neurosci 2007; 8: 610–22
- Batchelor T, Sorensen G, di Tomaso E, Zhang W-T, Guda D, et al. AZD2171, a pan VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell 2007; 11: 83–95
- Sathornsumetee, Cao Y, Marcello JE, Herndon II JE, McLendon RE, Desjardins A. Tumor angiogenic and hypoxic profiles predict radiographic response and survival in malignant astrocytoma patients treated with bevacizumab and irinotecan. J Clin Oncol 2008;26:271–8.
- Lai A, Filka E, McGibbon B, Nghiemphu PI, Graham C, Yong W, et al. Phase II pilot study of bevacizumab in combination with temozolomide and radiotherapy for up-front treatment of patients with newly diagnosed glioblastoma multiforme: Interimanalysis of safety and tolerability. Int J Radiat Oncol Biol Phys 2008; 71: 1372–80
- Ananthnarayan S, Bahng J, Roring J, Nghiemphu P, Lai A, et al Time course of imaging changes of GBM during extended bevacizumab treatment. J Neurooncol 2008.
- Cloughesy TF, Prados MD, Wen PY, Mikkelsen T, Abrey LE, Schiff D, et al A phase II, randomized, non-comparative clinical trial of the effect of bevacizumab (BV) alone or in combination with irinotecan (CPT) on 6-month progression free survival (PFS6) in recurrent, treatment-refractory glioblastoma (GBM). ASCO 2008, Chigaco. Abstract 2010b.